All In Biotech

Drug Trial Radar · NCT04303169

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Jun 26, 2020

Primary completion

Sep 24, 2025

Study completion Sep 24, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. Arm 1: Pembrolizumab + Vibostolimab, Arm 2: Pembrolizumab + Gebasaxturev, and Arm 3: Pembrolizumab were added in the base protocol on 13-Nov-2019, and enrollment into those arms has been completed. Arm 4: Pembrolizumab + MK-4830 was added in Amendment 04 on 20-Dec-2021, and enrollment into that arm has been completed. Arm 5: Favezelimab + Pembrolizumab and Arm 6: Pembrolizumab + all-trans retinoic acid (ATRA) were added in Amendment 06 on 25-Jun-2022, and enrollment is ongoing.

Conditions

  • Melanoma

Interventions

  • PembrolizumabBiological

    Administered via IV infusion at a specified dose on specified days

  • VibostolimabBiological

    Administered via IV infusion at a specified dose on specified days

  • GebasaxturevBiological

    Administered via IT injection at a specified dose on specified days

  • MK-4830Biological

    Administered via IV infusion at a specified dose on specified days

  • Favezelimab + PembrolizumabBiological

    Administered via IV infusion at a specified dose on specified days

  • ATRADrug

    Administered via oral capsules at a specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 17 months
  2. Percentage of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 13 months
  3. Pathological Complete Response (pCR) Rate With 90% Confidence Interval (CI)Time frame: Up to approximately 6 weeks
  4. pCR Rate With 95% CITime frame: Up to approximately 6 weeks

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute ( Site 3009)

    Los Angeles, California

  • Providence Saint John's Health Center ( Site 3010)

    Santa Monica, California

  • University of Colorado, Anschutz Cancer Pavilion ( Site 3012)

    Aurora, Colorado

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 3022)

    Baltimore, Maryland

  • NYU Clinical Cancer Center ( Site 3002)

    New York, New York

  • Duke Cancer Institute ( Site 3005)

    Durham, North Carolina

  • Martha Morehouse Tower ( Site 3020)

    Columbus, Ohio

  • Oregon Health & Science University ( Site 3013)

    Portland, Oregon

  • University of Pennsylvania Abramson Cancer Center ( Site 3008)

    Philadelphia, Pennsylvania

  • West Cancer Center - East Campus ( Site 3014)

    Germantown, Tennessee

  • Inova Schar Cancer Institute ( Site 3011)

    Fairfax, Virginia

  • Melanoma Institute Australia ( Site 3402)

    Wollstonecraft, New South Wales, Australia

  • Tasman Oncology Research Pty Ltd ( Site 3403)

    Southport, Queensland, Australia

  • Fiona Stanley Hospital ( Site 3401)

    Murdoch, Western Australia, Australia

  • A.P.H. Paris, Hopital Saint Louis ( Site 3107)

    Paris, France

  • Hopital La Timone ( Site 3103)

    Marseille, Bouches-du-Rhone, France

  • Institut Claudius Regaud ( Site 3105)

    Toulouse, Haute-Garonne, France

  • Gustave Roussy ( Site 3101)

    Villejuif, Île-de-France Region, France

  • Centre Hospitalier Lyon Sud ( Site 3102)

    Pierre-Bénite, Rhone, France

  • HaEmek Medical Center ( Site 3703)

    Afula, Israel

  • Rambam Health Care Campus-Oncology ( Site 3704)

    Haifa, Israel

  • Hadassah Ein Karem Jerusalem ( Site 3702)

    Jerusalem, Israel

  • Rabin Medical Center-Oncology ( Site 3705)

    Petah Tikva, Israel

  • Chaim Sheba Medical Center ( Site 3701)

    Ramat Gan, Israel

  • Istituto Europeo di Oncologia ( Site 3301)

    Milan, Italy

  • Policlinico Le Scotte - A.O. Senese ( Site 3377)

    Siena, Italy

  • Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 3603)

    Geneva, Canton of Geneva, Switzerland

  • CHUV Centre Hospitalier Universitaire Vaudois ( Site 3602)

    Lausanne, Canton of Vaud, Switzerland

  • Universitaetsspital Zuerich ( Site 3601)

    Zuerich Flughafen, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.